Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Coletti2020 - QSP model of prostate cancer immunotherapy

ABSTRACT: This model is based on the publication: Coletti R, Leonardelli L, Parolo S, Marchetti L. A QSP model of prostate cancer immunotherapy to identify effective combination therapies. Sci Rep. 2020 Jun 3;10(1):9063. doi: 10.1038/s41598-020-65590-0 Comment: Eq. 3 - no listed species "R", therefore based on Eq. 1 and 2, R_2 used instead. Eq. 12 - no listed parameter "a_Df" in Table S1, a_Dc used based on parameter description. Curation Comment: Simulations are not reproducing manuscript plots. Matlab code is available (Supplementary File 2 of the manuscript publication) but has not been tested, so would be worth reattempting model curation.

DISEASE(S): Prostate Cancer

SUBMITTER: Emilia Chen

PROVIDER: MODEL2109110002 | BioModels | 2021-09-11

REPOSITORIES: BioModels

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	MODEL2109110002?filename=Coletti2020.cps	Other
	MODEL2109110002?filename=Coletti2020.xml	Xml

Items per page:

1 - 2 of 2

Publications

A QSP model of prostate cancer immunotherapy to identify effective combination therapies.

Coletti Roberta R Leonardelli Lorena L Parolo Silvia S Marchetti Luca L

Scientific reports 20200603 1

Immunotherapy, by enhancing the endogenous anti-tumor immune responses, is showing promising results for the treatment of numerous cancers refractory to conventional therapies. However, its effectiveness for advanced castration-resistant prostate cancer remains unsatisfactory and new therapeutic strategies need to be developed. To this end, systems pharmacology modeling provides a quantitative framework to test in silico the efficacy of new treatments and combination therapies. In this paper we ...[more]

PMID: 32493951

Similar Datasets

Bakshi2020 - Minimal model of alternative pathway of complement system

Project description:This model is based on the publication: "Mathematical Modelling of Alternative Pathway of Complement System". Suruchi Bakshi, Fraser Cunningham, Eva-Maria Nichols, Marta Biedzka-Sarek, Jessica Neisen, Sebastien Petit-Frere, Christina Bessant, Loveleena Bansal, Lambertus A Peletier, Stefano Zamuner, Piet H van der Graaf DOI: 10.1007/s11538-020-00708-z Comment: This model is based on the truncated minimal model equations (Eq. B.1) from the manuscript, which simulate depletion of factor H. Abstract: The complement system (CS) is an integral part of innate immunity and can be activated via three different pathways. The alternative pathway (AP) has a central role in the function of the CS. The AP of complement system is implicated in several human disease pathologies. In the absence of triggers, the AP exists in a time-invariant resting state (physiological steady state). It is capable of rapid, potent and transient activation response upon challenge with a trigger. Previous models of AP have focused on the activation response. In order to understand the molecular machinery necessary for AP activation and regulation of a physiological steady state, we built parsimonious AP models using experimentally supported kinetic parameters. The models further allowed us to test quantitative roles played by negative and positive regulators of the pathway in order to test hypotheses regarding their mechanisms of action, thus providing more insight into the complex regulation of AP.

2024-09-02 | BIOMD0000001017 | BioModels

Bakshi2020 - Truncated minimal model of alternative pathway of complement system

2024-09-02 | BIOMD0000001016 | BioModels

Single cell RNA-seq data of human hESCs comparing experiments with cDNA library equalization

Project description:Considerable effort has been devoted to refining experimental protocols having reduced levels of technical variability and artifacts in single-cell RNA-sequencing data (scRNA-seq). We here present evidence that equalizing the concentration of cDNA libraries prior to pooling, a step not consistently performed in single-cell experiments, improves gene detection rates, enhances biological signals, and reduces technical artifacts in scRNA-seq data. In this submission the original single-cell cDNA is from GSE75748 cells labelled EC2 and TB2 in which the cDNA was not equalized prior to library preparation. We performed a set of experiments with the equalization step and provide three count matrices - 1) EQ (equalized cDNA prior to pooling in equal amounts); 2) EQ Vary (same as EQ but pooled at unequal amounts); 3) EQ-75% (equalized cDNA and pooled equally, sequeced to lower total depth).

2021-11-03 | GSE156494 | GEO

Human whole blood microarray study to compare patients with tuberculosis, sarcoidosis, pneumonia, and lung cancer

Project description:This SuperSeries is composed of the SubSeries listed below. [Third party comment] Samples with identical non-normalized expression values are identified at: https://colab.research.google.com/drive/1swvQGf-ZLAWnZw-7bOCmsypzzAnCDGUR#scrollTo=mIqv_oTHc6ns

2013-10-31 | GSE42834 | GEO

Expression analysis of transgenic embryos carrying the mitf-BRAFV600E allele in the presence or absence of p53 function

Project description:Investigation of expression differences between melanomas harvested from MiniCoopR-GFP versus MiniCoopR-SETDB1 transgenic zebrafish The embryos described in this study are further analyzed in a manuscript submitted for publication by White, et al.

2011-03-30 | GSE24529 | GEO

DNA methyltransferase inhibitor 5-aza-dC-treated prostate cancer cell lines

Project description:This microarray dataset accompanies the publication by Kim et al, "The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer". The dataset comprises four prostate cancer cell lines treated with the DNA methyltransferase inhibitor 5-aza-dC. For each cell line, gene expression in treated (channel 2; Cy5) and untreated (channel 1; Cy3) cells is directly compared by hybridization to the same DNA microarray. Further details on the treatment conditions are provided in the manuscript. A compound treatment design type is where the response to administration of a compound or chemical (including biological compounds such as hormones) is assayed. Keywords: compound_treatment_design

2006-01-25 | GSE4089 | GEO

Expression analysis of zebrafish melanoma and skin from the mitf-BRAFV600E;p53-/- line

Project description:Investigation of expression differences between skin and melanomas from a transgenic BRAFV600E zebrafish model of melanoma The embryos described in this study are further analyzed in a manuscript submitted for publication by White, et al.

2011-03-30 | GSE24528 | GEO

Chaudhury2020 - First order expansion model of CAR-T cell and tumour kinetics

Project description:This ordinary differential equation model of the cellular kinetics and pharmacodynamics of CAR-T cell therapy is described in the publication: Chaudhury, A., Zhu, X., Chu, L., Goliaei, A., June, C., Kearns, J. and Stein, A., 2020. Chimeric Antigen Receptor T Cell Therapies: A Review of Cellular Kinetic‐Pharmacodynamic Modeling Approaches. The Journal of Clinical Pharmacology, 60(S1). DOI: 10.1002/jcph.1691 Comment: This model is based on equations S1-S3 from the manuscript's supplemental information. A version of the approximated model, based on equations S4-S6, has been encoded separately. Curation Comment: There is a simulation error that has been attempted to be troubleshooted, however curation would be worth attempting again.

2021-09-11 | MODEL2109110005 | BioModels

Mullinax2016 - Mathematical model of tumor-immune cell interactions to optimize the meta-phenotype of TIL subpopulations

Project description:This model is described in the publication: John Mullinax, Cliona O’Farrelly, Jacob G. Scott, Andreas Buttenschön, Asmaa E. Elkenawi, Fadoua El Moustaid, Alexander G. Fletcher, Clemens Grassberger, Eunjung Kim, Andriy Marusyk, Harry L.O. McClelland, Daria Miroshnychenko, Daniel Nichol. "Harnessing the lymphocyte meta-phenotype to optimize adoptive cell therapy". bioRxiv 085910; doi: 10.1101/085910 Curation Comment: Figure 4 could not be reproduced. Attempted changing parameter values for Fig. 4(D) simulation, but plots were still not exact match for all species.

2021-09-11 | MODEL2109110006 | BioModels

Caruso2020 - Activation of the alternative complement pathway and effects on hemolysis

Project description:This model is based on the publication: Caruso A, Vollmer J, Machacek M, Kortvely E. "Modeling the activation of the alternative complement pathway and its effects on hemolysis in health and disease." PLoS Comput Biol. 2020 Oct 2;16(10):e1008139. doi: 10.1371/journal.pcbi.1008139 Curation Comment: Figure 4 has not been able to be reproduced, however authors are in the process of appending the model code to the publication.

2021-09-11 | MODEL2109110001 | BioModels

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data